Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …

Over the last five decades, a large body of evidence has accrued for structural and metabolic
brain alterations in schizophrenia. Here we provide an overview of these findings, focusing …

Observational studies have reported the correlations between brain imaging-derived
phenotypes (IDPs) and psychiatric disorders; however, whether the relationships are causal …

This review summarizes the last decade of work by the ENIGMA (E nhancing N euro I
maging G enetics through M eta A nalysis) Consortium, a global alliance of over 1400 …

Complement proteins facilitate synaptic elimination during neurodevelopmental pruning, but
neural complement regulation is not well understood. CUB and Sushi Multiple Domains 1 …

This review compares the main brain abnormalities in schizophrenia (SZ), bipolar disorder
(BD), major depressive disorder (MDD), and 22q11. 2 Deletion Syndrome (22q11DS) …

Schizophrenia is associated with widespread alterations in subcortical brain structure. While
analytic methods have enabled more detailed morphometric characterization, findings are …

What have we accomplished for schizophrenia patients since the introduction of
chlorpromazine in 1952 (1)? Have we really made a difference in the outcome of …

MRI‐derived brain measures offer a link between genes, the environment and behavior and
have been widely studied in bipolar disorder (BD). However, many neuroimaging studies of …

Neuroimaging findings in people at either genetic risk or at clinical high-risk for psychosis
(CHR-P) or bipolar disorder (CHR-B) remain unclear. A meta-analytic review of whole-brain …